Literature DB >> 12021166

Perspective: prostate cancer susceptibility genes.

Jacques Simard1, Martine Dumont, Penny Soucy, Fernand Labrie.   

Abstract

In many developed countries, prostate cancer is the most frequently diagnosed malignancy in men. The extent to which the marked racial/ethnic difference in its incidence rate is attributable to screening methods, environmental, hormonal, and/or genetic factors remains unknown. A positive family history is among the strongest epidemiological risk factors for prostate cancer. It is now well recognized that association of candidate genetic markers to this multifactorial malignancy is more difficult than the identification of susceptibility genes for some common cancers such as breast, ovary, and colon cancer. Several reasons may explain such a difficulty: 1) prostate cancer is diagnosed at a late age, thus often making it impossible to obtain DNA samples from living affected men for more than one generation; 2) the presence within high-risk pedigrees of phenocopies, associated with the lack of distinguishing features between hereditary and sporadic forms; and 3) the genetic heterogeneity of this complex disease along with the accompanying difficulty of developing appropriate statistical transmission models taking into account simultaneously multiple susceptibility genes, frequently showing moderate or low penetrance. Despite the localization of seven susceptibility loci, there has been limited confirmatory evidence of linkage for currently known candidate genes. Nonetheless, the discovery of the first prostate cancer susceptibility gene characterized by positional cloning, ELAC2 was achieved taking advantage of the Utah Family Resource. Moreover, common missense mutations in the ELAC2 gene were found to be significantly associated with an increased risk of diagnosis of prostate cancer in some studies. More recently, recombination map-ping and candidate gene analysis were used to map several genes, including the 2'-5'-oligoadenylate-dependent ribonuclease L (RNASEL) gene, to the critical region of HPC1. Two deleterious mutations in RNASEL segregate independently with the disease in two of the eight HPC1-linked families. Additional studies using larger cohorts are needed to fully evaluate the role of these two susceptibility genes in prostate cancer risk. Although a number of rare highly penetrant loci contribute to the Mendelian inheritance of prostate cancer, some of the familial risks may be due to shared environment and more specifically to common low-penetrance genetic variants. In this regard, it is not surprising that analyses of genes encoding key proteins involved in androgen biosynthesis and action, led to the observation of a significant association between a susceptibility to prostate cancer and common genetic variants, such as those found in 5alpha-reductase type 2 and AR genes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12021166     DOI: 10.1210/endo.143.6.8890

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  9 in total

1.  Tagging SNPs in the kallikrein genes 3 and 2 on 19q13 and their associations with prostate cancer in men of European origin.

Authors:  Prodipto Pal; Huifeng Xi; Guangyun Sun; Ritesh Kaushal; Joshua J Meeks; C Shad Thaxton; Saurav Guha; Carol H Jin; Brian K Suarez; William J Catalona; Ranjan Deka
Journal:  Hum Genet       Date:  2007-06-26       Impact factor: 4.132

2.  Variants in the HEPSIN gene are associated with prostate cancer in men of European origin.

Authors:  Prodipto Pal; Huifeng Xi; Ritesh Kaushal; Guangyun Sun; Carol H Jin; Li Jin; Brian K Suarez; William J Catalona; Ranjan Deka
Journal:  Hum Genet       Date:  2006-06-17       Impact factor: 4.132

3.  Nanotherapy silencing the interleukin-8 gene produces regression of prostate cancer by inhibition of angiogenesis.

Authors:  Ravikumar Aalinkeel; Bindukumar Nair; Chih-Kuang Chen; Supriya D Mahajan; Jessica L Reynolds; Hanguang Zhang; Haotian Sun; Donald E Sykes; Kailash C Chadha; Steven G Turowski; Katelyn D Bothwell; Mukund Seshadri; Chong Cheng; Stanley A Schwartz
Journal:  Immunology       Date:  2016-08       Impact factor: 7.397

4.  Xenotropic murine leukemia virus-related virus is susceptible to AZT.

Authors:  Ryuta Sakuma; Toshie Sakuma; Seiga Ohmine; Robert H Silverman; Yasuhiro Ikeda
Journal:  Virology       Date:  2009-12-02       Impact factor: 3.616

5.  Expression profile of microRNAs in c-Myc induced mouse mammary tumors.

Authors:  Yuan Sun; Jack Wu; Si-hung Wu; Archana Thakur; Aliccia Bollig; Yong Huang; D Joshua Liao
Journal:  Breast Cancer Res Treat       Date:  2008-09-07       Impact factor: 4.872

6.  No evidence of XMRV in prostate cancer cohorts in the Midwestern United States.

Authors:  Toshie Sakuma; Stéphane Hué; Karen A Squillace; Jason M Tonne; Patrick R Blackburn; Seiga Ohmine; Tayaramma Thatava; Greg J Towers; Yasuhiro Ikeda
Journal:  Retrovirology       Date:  2011-03-29       Impact factor: 4.602

7.  Identification of Two Novel HOXB13 Germline Mutations in Portuguese Prostate Cancer Patients.

Authors:  Sofia Maia; Marta Cardoso; Pedro Pinto; Manuela Pinheiro; Catarina Santos; Ana Peixoto; Maria José Bento; Jorge Oliveira; Rui Henrique; Carmen Jerónimo; Manuel R Teixeira
Journal:  PLoS One       Date:  2015-07-15       Impact factor: 3.240

Review 8.  Epigenetics of prostate cancer: beyond DNA methylation.

Authors:  W A Schulz; J Hatina
Journal:  J Cell Mol Med       Date:  2006 Jan-Mar       Impact factor: 5.310

9.  Role of Genetic Polymorphisms in the Development and Prognosis of Sporadic and Familial Prostate Cancer.

Authors:  Sabrina T Reis; Nayara I Viana; Katia R M Leite; Erico Diogenes; Alberto A Antunes; Alexandre Iscaife; Adriano J Nesrallah; Carlo C Passerotti; Victor Srougi; José Pontes-Junior; Mary Ellen Salles; William C Nahas; Miguel Srougi
Journal:  PLoS One       Date:  2016-12-01       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.